Technical Data
E3375-10F1
Epidermal Growth Factor Receptor (erbB, EGFR) (FITC)
Description:
The EGF receptor (EGFR), a 180kD transmembrane tyrosine kinase, is part of the ErbB family which mediate ligand induced signaling as heterodimers. Ligand binding results in activation of the intrinsic kinase activity and autophosphorylation on tyrosine residues within and surrounding the kinase domain. The phospho-tyrosine residues serve as docking sites for adapter proteins that nucleate signaling complexes that result in the activation of the Ras, PI-3 kinase and PLC-g pathways. EGFR, which transduces the biological effects of EGF and TGF-a, is frequently over-expressed in solid tumors.

Applications:
Suitable for use in Flow Cytometry. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1:10, Use 10ul to label 10e6 cells in 100ul.
Optimal dilutions to be determined by the researcher.

Recommended Negative Controls:
I1904-82E2: IgG2a Rat Negative Control (FITC)

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.FITC conjugates are sensitive to light.
TypeIsotypeCloneGrade
MabIgG2a3H2090Highly Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanRat
Concentration:
~0.1mg/ml
Immunogen:
Extracellular domain of human EGF-receptor from head and neck carcinoma.
Purity:
Purified by Ion Exchange chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.09% sodium azide. Labeled with fluorescein isothiocyanate (FITC).
Specificity:
Recognizes the human epidermal growth factor receptor (EGF-R), which is overexpressed in a high proportion of breast cancer cells and in a range of other carcinomas. Binds to epitope B from EGFR (1, 2) and has an affinity of 6.7 x 10e-9 M.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Modjtahedi, H. and Dean, C.J. (1994) Int. J. Oncol. 4:277-296.